封面
市場調查報告書
商品編碼
1410905

核醫學成像顯影劑的全球市場 - 市場規模(各市場區隔),佔有率,法規,償付,預測(~2033年)

Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

出版日期: | 出版商: GlobalData | 英文 | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

本報告提供全球核醫學成像顯影劑市場相關調查分析,提供各市場區隔的市場規模,市場趨勢,競爭情形,COVID-19影響等資訊。

市場模式的主要內容如下列。

已上市的核醫學成像顯影劑與不斷變化的競爭格局

  • 主要的產業趨勢考察
  • 核醫學成像顯影劑市場區隔的年度收益與市場預測(2015年~2033年)
  • 台數,平均銷售價格,市場金額相關市場層級的資料

世界,地區,國家層級的市場固有考察

  • 各地區分類的全球趨勢之定性市場固有資訊與各國考察
  • 核醫學成像顯影劑市場SWOT分析
  • 核醫學成像顯影劑市場競爭動態的考察和趨勢

透過掌握包含醫療制度概要的真實整體狀況來促進對市場的認識。此外在打入市場部門更提供關於給付原則及法規情勢之資訊,使您能夠更深入地研究市場動態。

  • 各國醫療制度概要
  • 各國償付政策
  • 各國醫療技術相關法規形勢

對象企業

  • Cardinal Health Inc
  • GE Healthcare
  • Advanced Accelerator Applications SA
  • Bracco Diagnostics Inc
  • Lantheus Holdings Inc
  • 其他

Abstract

Nuclear Imaging Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within Diagnostic Imaging therapeutic area.

The model discusses in detail the impact of COVID-19 on Nuclear Imaging Agents market for the year 2020 and beyond. Nuclear Imaging is a noninvasive medical technique which uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases. The diseases include cancers, cardiac diseases, gastrointestinal, endocrine and neurological diseases.

Nuclear Imaging Agents's have been classified into Positron Emission Tomography (PET) Systems and Single Photon Emission Computed Tomography (SPECT) Systems. The advanced version of these systems include PET/CT, PET/MRI, SPECT/CT and SPECT/MRI. These systems contain features of both PET and CT/MRI and SPECT and CT/MRI.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Nuclear Imaging Agents and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Nuclear Imaging Agents market revenue by segment and market outlooks from 2015-2033.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Nuclear Imaging Agents market.
  • Competitive dynamics insights and trends provided for Nuclear Imaging Agents market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Cardinal Health Inc, GE Healthcare, Advanced Accelerator Applications SA, Bracco Diagnostics Inc, Lantheus Holdings Inc and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Nuclear Imaging Agents marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Nuclear Imaging Agents market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Nuclear Imaging Agents market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Nuclear Imaging Agents market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Nuclear Imaging Agents market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable